evipedia.ai
← Back

TB-500 for Health & Longevity

Created on 10/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

TB-500, a laboratory-made peptide copying part of a repair protein the body makes, is sold as an injection for recovery from tendon, muscle and joint injury. No human study has tested it; trials of the full protein it copies, administered by other routes, were mixed. Animal work is more encouraging. Main risks: products not matching their labels, no lawful consumer supply, and unclear safety with undetected cancer or eye disease. (Full Review)

Protocol

No validated human dose
Indication, dose, frequency and duration unknown
Any figure in circulation is practice, not evidence
Circulating gray-market regimen
About 2–2.5 mg twice weekly
Subcutaneous, for 4 to 6 weeks, then once weekly; no trial supports these numbers
Single versus split dosing
Weekly amount split across two injections
Common choice; no drug-level study in people compares split with single administration
Time to effect
Tendon repair (rats)
4 weeks
Tested with TB-500 itself; no human timeline exists
Injury recovery (practice)
4–6 weeks
Users typically judge effect within this block, also the window in which natural healing occurs

Benefits

Contraindications
  • Anyone with active, metastatic or recently treated cancer
  • People with proliferative diabetic retinopathy or neovascular macular degeneration
  • Pregnant or breastfeeding people
  • Competitive athletes under an anti-doping code
    •
Key Interactions
Theoretical (inferred from mechanism)
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, apixaban, warfarin)
  • Supplements with antiplatelet activity (fish oil, ginkgo, high-dose vitamin E)
  • Anti-angiogenic cancer therapy and intra-ocular anti-VEGF injections (bevacizumab, aflibercept)
  • Systemic corticosteroids (prednisone, dexamethasone)
  • Other peptides combined in the same cycle (BPC-157, GHK-Cu, ipamorelin)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection-site and general adverse events; antibody formation against the injected peptide
    •
  • Speculative: Mislabeled or adulterated product content; hypersensitivity and severe allergic-type reactions; tumour growth and spread; pathological blood-vessel growth; transient rise in a tumour marker
    •

Monitoring

Marker Target Why
ALT 7-56 U/L Liver safety check
AST Not specified in the ER Paired liver safety check
Bilirubin Not specified in the ER Paired liver safety check
Creatinine with eGFR Creatinine: men 0.74-1.35 mg/dL, women 0.59-1.04 mg/dL Detects kidney injury
Complete blood count (white cell count) 4.0-11.0 ×10⁹/L Flags infection from self-injection
hs-CRP 0.0-3.0 mg/L Flags infection or inflammatory reaction

Cadence: Baseline before any cycle, with age-appropriate cancer screening and, for anyone with diabetes, a dilated retinal examination; panel repeated at around four weeks and at cycle end (usually 8 to 12 weeks), then every 6 to 12 months if use continues

Qualitative Assessment

  • Pain at the injured site, scored the same way each week
  • Range of motion and loaded function
  • Return to a specific activity at a specific load, defined before the cycle starts
  • Injection-site appearance: redness, swelling, lumps or persistent soreness
  • Any new skin lesion, mole change or visual symptom
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.